Adrenomedullin
PreclinicalSmall molecule
Adrenomedullin is one of 38 small molecule programs targeting Headache. It is currently in Preclinical.
2
Indications
3
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
102 competitors in Migraine
#DrugCompanyPhaseTrials
1Zonegran
AAzurity Pharmaceuticals
Phase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Magnesium
SSpherium Biomed
Phase 3
Triptans
PfizerPhase 3
Aspirin /d
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
Bayer Aspirin
BayerPreclinical
Cervidil
PfizerPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adrenomedullin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDanish Headache Center